Dysphagia in Patients with Sporadic Inclusion Body Myositis: Management Challenges

Nika Mohannak; Gemma Pattison; Kathryn Hird; Merrilee Needham

doi:10.2147/IJGM.S198031

Dysphagia in Patients with Sporadic Inclusion Body Myositis: Management Challenges

Int J Gen Med. 2019 Dec 5:12:465-474. doi: 10.2147/IJGM.S198031. eCollection 2019.

Authors

Nika Mohannak¹, Gemma Pattison², Kathryn Hird¹, Merrilee Needham^{1

3

4}

Affiliations

¹ School of Medicine, The University of Notre Dame, Fremantle, Western Australia, Australia.
² Department of Speech Pathology, Royal Perth Hospital, Perth, Western Australia, Australia.
³ Department of Neurology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.
⁴ Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia.

Abstract

Dysphagia in inclusion body myositis (IBM) is common and associated with increased mortality and morbidity due to aspiration pneumonia, malnutrition and dehydration. There is currently no consensus on treatment of dysphagia in IBM and outcomes are variable depending on timing of intervention, patient preference and available expertise. There is a paucity of research exploring the pathophysiology of dysphagia in IBM and appropriate investigations. Increased knowledge of the aetiopathogenesis is likely to change the approach to treatment as well as improve the quality of life for patients. This review explores the epidemiology and pathophysiology of dysphagia in IBM and the currently available treatment strategies.

Keywords: diagnosis; epidemiology; inflammatory myopathies; pathophysiology; swallowing; treatment.

Publication types

Review